[Form 3] Neuphoria Therapeutics Inc. Initial Statement of Beneficial Ownership
Neuphoria Therapeutics Inc. (NEUP) received an initial ownership report on Form 3.
Rhea-AI Filing Summary
Neuphoria Therapeutics Inc. (NEUP) received an initial ownership report on Form 3. The filing lists “Director” as the relationship to the issuer and indicates the form was filed by more than one reporting person. The event date is 10/21/2025.
The report shows 236,218 shares of common stock beneficially owned on an indirect basis, held by Lynx1 Master Fund LP. The filing explains that Lynx1 Capital Management LP serves as investment manager to the fund and Weston Nichols is the sole member of the fund manager’s general partner. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common stock, $0.00001 par value per share | -- | -- | -- |
Footnotes (1)
- F1. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
AI-generated analysis. How Rhea-AI works. Not financial advice.